Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Vaught

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
International Journal of Cancer|August 7, 1997
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activityA M Camoratto, J P Jani, T S Angeles, et al.
Journal of Neurobiology|June 13, 1998
CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivoM A Glicksman, A Y Chiu, C A Dionne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)C A Dionne, A M Camoratto, J P Jani, et al.
Journal of Medicinal Chemistry|April 15, 1994
A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effectsA B Reitz, D J Bennett, P S Blum, et al.
The Journal of Biological Chemistry|April 28, 2001
Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase familyA C Maroney, J P Finn, T J Connors, et al.
Journal of Medicinal Chemistry|June 6, 1997
Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivativesM Kaneko, Y Saito, H Saito, et al.
Journal of Medicinal Chemistry|June 17, 1998
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptorsA B Reitz, E W Baxter, E E Codd, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
International Journal of Cancer|August 7, 1997
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activityA M Camoratto, J P Jani, T S Angeles, et al.
Journal of Neurobiology|June 13, 1998
CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivoM A Glicksman, A Y Chiu, C A Dionne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)C A Dionne, A M Camoratto, J P Jani, et al.
Journal of Medicinal Chemistry|April 15, 1994
A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effectsA B Reitz, D J Bennett, P S Blum, et al.
The Journal of Biological Chemistry|April 28, 2001
Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase familyA C Maroney, J P Finn, T J Connors, et al.
Journal of Medicinal Chemistry|June 6, 1997
Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivativesM Kaneko, Y Saito, H Saito, et al.
Journal of Medicinal Chemistry|June 17, 1998
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptorsA B Reitz, E W Baxter, E E Codd, et al.
Pageof 8